Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
1998 5
1999 1
2000 5
2001 7
2002 14
2003 16
2004 17
2005 14
2006 15
2007 16
2008 5
2009 3
2010 5
2011 6
2012 8
2013 6
2014 7
2015 4
2016 4
2017 1
2018 2
2019 2
2020 3
2022 3
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

156 results
Results by year
Filters applied: . Clear all
Page 1
Tositumomab I 131.
[No authors listed] [No authors listed] 2022 May 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2022 May 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999771 Free Books & Documents. Review.
Information in this record refers to the use of tositumomab I 131 as a therapeutic agent. No information is available on the use of tositumomab I 131 during breastfeeding. ...Parents should limit close contact with their infants and small children afte …
Information in this record refers to the use of tositumomab I 131 as a therapeutic agent. No information is available on the u …
Tositumomab and iodine I 131 tositumomab (Bexaar).
Srinivasan A, Mukherji SK. Srinivasan A, et al. AJNR Am J Neuroradiol. 2011 Apr;32(4):637-8. doi: 10.3174/ajnr.A2593. Epub 2011 Mar 24. AJNR Am J Neuroradiol. 2011. PMID: 21436340 Free PMC article. Review.
Tositumomab and iodine I 131 tositumomab (Bexaar) therapeutic regimen targets monoclonal antibodies against the CD20 antigen expressed in non-Hodgkin lymphoma. ...
Tositumomab and iodine I 131 tositumomab (Bexaar) therapeutic regimen targets monoclonal antibodies against the
A clinical and scientific overview of tositumomab and iodine I 131 tositumomab.
Zelenetz AD. Zelenetz AD. Semin Oncol. 2003 Apr;30(2 Suppl 4):22-30. doi: 10.1053/sonc.2003.23803. Semin Oncol. 2003. PMID: 12728404 Review.
Hematologic toxicity is the major dose-limiting toxicity associated with radioimmunotherapy; however, patient-specific dosimetry maintained hematologic toxicity within predictable, transient, and manageable limits in the phase II and phase III trials of tositumomab and …
Hematologic toxicity is the major dose-limiting toxicity associated with radioimmunotherapy; however, patient-specific dosimetry maintained …
The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab.
Wahl RL. Wahl RL. Semin Oncol. 2003 Apr;30(2 Suppl 4):31-8. doi: 10.1053/sonc.2003.23799. Semin Oncol. 2003. PMID: 12728405 Review.
As with most drugs, there is considerable interpatient variability in the clearance rate (or total body residence time) of radioimmunoconjugates. The clearance rate of iodine I 131 tositumomab in clinical trials has varied by as much as five-fold. ...For the …
As with most drugs, there is considerable interpatient variability in the clearance rate (or total body residence time) of radioimmunoconjug …
Radioimmunotherapy with tositumomab and iodine-131 tositumomab for low-grade non-Hodgkin lymphoma: nursing implications.
Estes JM, Clapp KJ. Estes JM, et al. Oncol Nurs Forum. 2004 Nov 16;31(6):1119-26. doi: 10.1188/04.ONF.1119-1126. Oncol Nurs Forum. 2004. PMID: 15547634 Review.
PURPOSE/OBJECTIVES: To review radioimmunotherapy approaches for low-grade non-Hodgkin lymphoma (NHL) with a focus on tositumomab and iodine-131 tositumomab (Bexxar, Corixa Corporation, Seattle, WA, and GlaxoSmithKline, Philadelphia, PA). ...
PURPOSE/OBJECTIVES: To review radioimmunotherapy approaches for low-grade non-Hodgkin lymphoma (NHL) with a focus on tositumomab and …
Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members.
Rutar FJ, Augustine SC, Kaminski MS, Wahl RL, Siegel JA, Colcher D. Rutar FJ, et al. Clin Lymphoma. 2001 Dec;2(3):164-72. doi: 10.3816/clm.2001.n.022. Clin Lymphoma. 2001. PMID: 11779293 Review.
Non-Hodgkin's lymphoma patients have been studied to evaluate radiation exposure to caregivers/family members after outpatient treatment with tositumomab and iodine I 131 tositumomab (Bexxar therapy). Estimates of total radiation doses to individuals e …
Non-Hodgkin's lymphoma patients have been studied to evaluate radiation exposure to caregivers/family members after outpatient treatment wit …
Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.
Friedberg JW, Fisher RI. Friedberg JW, et al. Expert Rev Anticancer Ther. 2004 Feb;4(1):18-26. doi: 10.1586/14737140.4.1.18. Expert Rev Anticancer Ther. 2004. PMID: 14748653 Review.
Tositumomab is linked covalently with iodine-131 to produce the radioimmunoconjugate iodine-131 tositumomab (Bexxar). ...The dose-limiting toxicity of iodine-131 tositumomab is bone marrow suppression and resulting cy
Tositumomab is linked covalently with iodine-131 to produce the radioimmunoconjugate iodine-131 tositu
A review of tositumomab and I(131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma.
Davies AJ. Davies AJ. Expert Opin Biol Ther. 2005 Apr;5(4):577-88. doi: 10.1517/14712598.5.4.577. Expert Opin Biol Ther. 2005. PMID: 15934835 Review.
The CD20 antigen has become a major therapeutic target in the management of follicular and other B cell non-Hodgkin's lymphomas. The murine monoclonal antibody, tositumomab, on binding CD20, is able to induce antibody-dependent cellular cytotoxicity, complement-dependent c …
The CD20 antigen has become a major therapeutic target in the management of follicular and other B cell non-Hodgkin's lymphomas. The murine …
CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma.
Leonard JP, Gregory SA, Smith H, Horner TJ, Williams VC, Giampietro P, Lin TS. Leonard JP, et al. Clin Lymphoma Myeloma Leuk. 2016 Apr;16(4):191-6. doi: 10.1016/j.clml.2015.12.011. Epub 2016 Jan 4. Clin Lymphoma Myeloma Leuk. 2016. PMID: 26832194
The efficacy and safety of tositumomab/iodine-131 tositumomab (TST/I-131 TST) were evaluated in diffuse large B-cell lymphoma patients who responded to first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). ...Median overa …
The efficacy and safety of tositumomab/iodine-131 tositumomab (TST/I-131 TST) were evaluated in diffuse l …
Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.
Davies AJ, Rohatiner AZ, Howell S, Britton KE, Owens SE, Micallef IN, Deakin DP, Carrington BM, Lawrance JA, Vinnicombe S, Mather SJ, Clayton J, Foley R, Jan H, Kroll S, Harris M, Amess J, Norton AJ, Lister TA, Radford JA. Davies AJ, et al. J Clin Oncol. 2004 Apr 15;22(8):1469-79. doi: 10.1200/JCO.2004.06.055. J Clin Oncol. 2004. PMID: 15084620 Clinical Trial.
PURPOSE: An open-label phase II study was conducted at two centers to establish the efficacy and safety of tositumomab and iodine I 131 tositumomab at first or second recurrence of indolent or transformed indolent B-cell lymphoma. ...CONCLUSION: High o …
PURPOSE: An open-label phase II study was conducted at two centers to establish the efficacy and safety of tositumomab and iodine
156 results